Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 219

1.

High mobility group A1 (HMGA1) protein and gene expression correlate with ER-negativity and poor outcomes in breast cancer.

Gorbounov M, Carleton NM, Asch-Kendrick RJ, Xian L, Rooper L, Chia L, Cimino-Mathews A, Cope L, Meeker A, Stearns V, Veltri RW, Bae YK, Resar LMS.

Breast Cancer Res Treat. 2019 Sep 17. doi: 10.1007/s10549-019-05419-1. [Epub ahead of print]

PMID:
31531802
2.

Pathogenic Germline Variants in Patients With Metastatic Breast Cancer.

Stuttgen K, Croessmann S, Fetting J, Stearns V, Nunes R, Connolly RM, Park BH.

JAMA Oncol. 2019 Aug 29. doi: 10.1001/jamaoncol.2019.3116. [Epub ahead of print] No abstract available.

PMID:
31465090
3.

Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage Breast Cancer: Update Summary of ASCO Cancer Care Ontario Guideline Endorsement.

Henry NL, Somerfield MR, Stearns V.

J Oncol Pract. 2019 Jul 23:JOP1900266. doi: 10.1200/JOP.19.00266. [Epub ahead of print] No abstract available.

PMID:
31335247
4.

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update Summary.

Andre F, Ismaila N, Stearns V.

J Oncol Pract. 2019 Sep;15(9):495-497. doi: 10.1200/JOP.19.00264. Epub 2019 Jul 15. No abstract available.

PMID:
31306037
5.

Reply to E. Hindié et al.

Connolly RM, Huang CY, Stearns V, Wahl RL.

J Clin Oncol. 2019 Aug 10;37(23):2092-2093. doi: 10.1200/JCO.19.01078. Epub 2019 Jun 28. No abstract available.

PMID:
31251693
6.

Reply to H. Brauch et al.

Stearns V.

J Clin Oncol. 2019 Aug 1;37(22):1986. doi: 10.1200/JCO.19.00971. Epub 2019 Jun 18. No abstract available.

PMID:
31211605
7.

Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.

Henry NL, Somerfield MR, Abramson VG, Ismaila N, Allison KH, Anders CK, Chingos DT, Eisen A, Ferrari BL, Openshaw TH, Spears PA, Vikas P, Stearns V.

J Clin Oncol. 2019 Aug 1;37(22):1965-1977. doi: 10.1200/JCO.19.00948. Epub 2019 Jun 17.

PMID:
31206315
8.

Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole.

Dempsey JM, Kidwell KM, Gersch CL, Pesch AM, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM, Hertz DL.

Pharmacogenomics. 2019 Jun;20(8):571-580. doi: 10.2217/pgs-2019-0020.

PMID:
31190621
9.

Sharing in care: engaging care partners in the care and communication of breast cancer patients.

Wolff JL, Aufill J, Echavarria D, Heughan JA, Lee KT, Connolly RM, Fetting JH, Jelovac D, Papathakis K, Riley C, Stearns V, Thorner E, Zafman N, Levy HP, Dy SM, Wolff AC.

Breast Cancer Res Treat. 2019 Aug;177(1):127-136. doi: 10.1007/s10549-019-05306-9. Epub 2019 Jun 4.

PMID:
31165374
10.

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.

Andre F, Ismaila N, Henry NL, Somerfield MR, Bast RC, Barlow W, Collyar DE, Hammond ME, Kuderer NM, Liu MC, Van Poznak C, Wolff AC, Stearns V.

J Clin Oncol. 2019 Aug 1;37(22):1956-1964. doi: 10.1200/JCO.19.00945. Epub 2019 May 31.

PMID:
31150316
11.

Treatment Patterns and Outcomes Associated With Palbociclib Plus Letrozole for Postmenopausal Women With HR+/HER2- Advanced Breast Cancer Enrolled in an Expanded Access Program.

Brufsky A, Mitra D, Davis KL, Nagar SP, McRoy L, Cotter MJ, Stearns V.

Clin Breast Cancer. 2019 Oct;19(5):317-325.e4. doi: 10.1016/j.clbc.2019.04.005. Epub 2019 Apr 18.

12.

Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy.

Sheng JY, Blackford AL, Bardia A, Venkat R, Rosson G, Giles J, Hayes DF, Jeter SC, Zhang Z, Hayden J, Nguyen A, Storniolo AM, Tarpinian K, Henry NL, Stearns V.

Breast Cancer Res Treat. 2019 Aug;176(3):617-624. doi: 10.1007/s10549-019-05270-4. Epub 2019 May 11.

PMID:
31079282
13.

Intraductal fulvestrant for therapy of ERα-positive ductal carcinoma in situ of the breast: a preclinical study.

Wang G, Chen C, Pai P, Korangath P, Sun S, Merino VF, Yuan J, Li S, Nie G, Stearns V, Sukumar S.

Carcinogenesis. 2019 Jul 20;40(7):903-913. doi: 10.1093/carcin/bgz084.

PMID:
31046118
14.

Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.

Kamdem LK, Xi J, Clark BL, Gregory BJ, Kidwell KM, Storniolo AM, Stearns V, Hayes DF, Gersch CL, Rae JM, Henry NL, Hertz DL.

Breast Cancer Res Treat. 2019 Jun;175(2):297-303. doi: 10.1007/s10549-019-05158-3. Epub 2019 Feb 12.

PMID:
30747308
15.

TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.

Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V.

J Clin Oncol. 2019 Mar 20;37(9):714-722. doi: 10.1200/JCO.2018.78.7986. Epub 2019 Feb 5.

PMID:
30721110
16.

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.

Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ.

J Clin Oncol. 2019 Feb 10;37(5):423-438. doi: 10.1200/JCO.18.01160. Epub 2018 Nov 19.

PMID:
30452337
17.

Survivorship care visits in a high-risk population of breast cancer survivors.

Skuli SJ, Sheng JY, Bantug ET, Zafman N, Riley C, Ruck JM, Smith KC, Snyder CF, Smith KL, Stearns V, Wolff AC.

Breast Cancer Res Treat. 2019 Feb;173(3):701-708. doi: 10.1007/s10549-018-5028-z. Epub 2018 Nov 7.

PMID:
30406364
18.

Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.

Stearns V, Brufsky AM, Verma S, Cotter MJ, Lu DR, Dequen F, Joy AA.

Clin Breast Cancer. 2018 Dec;18(6):e1239-e1245. doi: 10.1016/j.clbc.2018.07.007. Epub 2018 Jul 30.

PMID:
30172722
19.

TAILORing Adjuvant Systemic Therapy for Breast Cancer.

Stearns V.

N Engl J Med. 2018 Jul 12;379(2):191-192. doi: 10.1056/NEJMe1806329. No abstract available.

PMID:
29996081
20.

Breast Hormone Concentrations in Random Fine-Needle Aspirates of Healthy Women Associate with Cytological Atypia and Gene Methylation.

Lee O, Heinz RE, Ivancic D, Muzzio M, Chatterton RT, Zalles CM, Keeney K, Phan B, Liu D, Scholtens D, Fackler MJ, Stearns V, Sukumar S, Khan SA.

Cancer Prev Res (Phila). 2018 Sep;11(9):557-568. doi: 10.1158/1940-6207.CAPR-17-0323. Epub 2018 Jun 28.

21.

PIK3CA Mutations in Hormone Receptor-Positive Breast Cancers: PIKing Biomarkers to Inform Adjuvant Endocrine Therapy Decisions.

Stearns V, Park BH.

JAMA Oncol. 2018 Oct 1;4(10):1330-1332. doi: 10.1001/jamaoncol.2018.1766. No abstract available.

PMID:
29902310
22.

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE Jr, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM; SOFT and TEXT Investigators and the International Breast Cancer Study Group.

N Engl J Med. 2018 Jul 12;379(2):122-137. doi: 10.1056/NEJMoa1803164. Epub 2018 Jun 4.

23.

CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor–Positive Advanced Breast Cancer?

Shah M, Nunes MR, Stearns V.

Oncology (Williston Park). 2018 May 15;32(5):216-22. Review.

24.

A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.

Santa-Maria CA, Bardia A, Blackford AL, Snyder C, Connolly RM, Fetting JH, Hayes DF, Jeter SC, Miller RS, Nguyen A, Quinlan K, Rosner GL, Slater S, Storniolo AM, Wolff AC, Zorzi J, Henry NL, Stearns V.

Breast Cancer Res Treat. 2018 Aug;171(1):121-129. doi: 10.1007/s10549-018-4811-1. Epub 2018 May 11.

25.

Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors.

Jacobs MA, Macura KJ, Zaheer A, Antonarakis ES, Stearns V, Wolff AC, Feiweier T, Kamel IR, Wahl RL, Pan L.

Acad Radiol. 2018 Nov;25(11):1405-1414. doi: 10.1016/j.acra.2018.02.010. Epub 2018 Apr 4.

26.

Adiposity Results in Metabolic and Inflammation Differences in Premenopausal and Postmenopausal Women Consistent with the Difference in Breast Cancer Risk.

Zhao H, Wang J, Fang D, Lee O, Chatterton RT, Stearns V, Khan SA, Bulun SE.

Horm Cancer. 2018 Aug;9(4):229-239. doi: 10.1007/s12672-018-0329-6. Epub 2018 Mar 15.

PMID:
29546532
27.

Increasing Physical Activity Amongst Overweight and Obese Cancer Survivors Using an Alexa-Based Intelligent Agent for Patient Coaching: Protocol for the Physical Activity by Technology Help (PATH) Trial.

Hassoon A, Schrack J, Naiman D, Lansey D, Baig Y, Stearns V, Celentano D, Martin S, Appel L.

JMIR Res Protoc. 2018 Feb 12;7(2):e27. doi: 10.2196/resprot.9096.

28.

Complete Response to Single-agent Palbociclib in Metastatic Breast Cancer: A Case Report.

Yeruva SLH, Javadi MS, Stearns V.

Clin Breast Cancer. 2018 Jun;18(3):e277-e280. doi: 10.1016/j.clbc.2017.12.008. Epub 2017 Dec 21. No abstract available.

29.

Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer.

Litvak A, Batukbhai B, Russell SD, Tsai HL, Rosner GL, Jeter SC, Armstrong D, Emens LA, Fetting J, Wolff AC, Silhy R, Stearns V, Connolly RM.

Cancer. 2018 May 1;124(9):1904-1911. doi: 10.1002/cncr.31260. Epub 2018 Jan 30.

30.

Reply to J.L. Blum et al and S. Lange et al.

Krop I, Ismaila N, Barlow W, Stearns V.

J Clin Oncol. 2018 Feb 1;36(4):430-431. doi: 10.1200/JCO.2017.75.8607. Epub 2017 Dec 11. No abstract available.

PMID:
29227726
31.

Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design.

Ligibel JA, Barry WT, Alfano C, Hershman DL, Irwin M, Neuhouser M, Thomson CA, Delahanty L, Frank E, Spears P, Paskett ED, Hopkins J, Bernstein V, Stearns V, White J, Hahn O, Hudis C, Winer EP, Wadden TA, Goodwin PJ.

NPJ Breast Cancer. 2017 Sep 21;3:37. doi: 10.1038/s41523-017-0040-8. eCollection 2017. Review.

32.

Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008.

Connolly RM, Fackler MJ, Zhang Z, Zhou XC, Goetz MP, Boughey JC, Walsh B, Carpenter JT, Storniolo AM, Watkins SP, Gabrielson EW, Stearns V, Sukumar S.

Breast Cancer Res Treat. 2018 Jan;167(1):107-116. doi: 10.1007/s10549-017-4503-2. Epub 2017 Sep 16.

33.

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Focused Update Guideline Summary.

Krop I, Ismaila N, Stearns V.

J Oncol Pract. 2017 Nov;13(11):763-766. doi: 10.1200/JOP.2017.024646. Epub 2017 Jul 11. No abstract available.

PMID:
28696818
34.

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.

Krop I, Ismaila N, Andre F, Bast RC, Barlow W, Collyar DE, Hammond ME, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Wolff AC, Stearns V.

J Clin Oncol. 2017 Aug 20;35(24):2838-2847. doi: 10.1200/JCO.2017.74.0472. Epub 2017 Jul 10.

35.

Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients.

Hertz DL, Speth KA, Kidwell KM, Gersch CL, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM.

Breast Cancer Res Treat. 2017 Oct;165(3):659-668. doi: 10.1007/s10549-017-4346-x. Epub 2017 Jun 22.

36.

Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors.

Kadakia KC, Kidwell KM, Seewald NJ, Snyder CF, Storniolo AM, Otte JL, Flockhart DA, Hayes DF, Stearns V, Henry NL.

Breast Cancer Res Treat. 2017 Jul;164(2):411-419. doi: 10.1007/s10549-017-4260-2. Epub 2017 Apr 27.

37.

Use of Geriatric Assessment Tools in Selecting Therapies in Women Aged ≥70 Years With Hormone Receptor-Positive Early-Stage Breast Cancer: Preliminary Experience With a Quality Improvement Initiative.

Wright JL, Parekh A, Pollock YY, Schoenborn N, Smith KL, Magnant C, Stearns V.

Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):884-890. doi: 10.1016/j.ijrobp.2017.01.210. Epub 2017 Jan 29.

PMID:
28366577
38.

The relationship of single-strand breaks in DNA to breast cancer risk and to tissue concentrations of oestrogens.

Sahadevan M, Lee O, Muzzio M, Phan B, Jacobs L, Khouri N, Wang J, Hu H, Stearns V, Chatterton RT.

Biomarkers. 2017 Nov;22(7):689-697. doi: 10.1080/1354750X.2017.1293736. Epub 2017 Feb 28.

PMID:
28276926
39.

Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board.

Dalton WB, Forde PM, Kang H, Connolly RM, Stearns V, Gocke CD, Eshleman JR, Axilbund J, Petry D, Geoghegan C, Wolff AC, Loeb DM, Pratilas CA, Meyer CF, Christenson ES, Slater SA, Ensminger J, Parsons HA, Park BH, Lauring J.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.16.00046. Epub 2017 May 31.

40.

Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.

Kim HS, Umbricht CB, Illei PB, Cimino-Mathews A, Cho S, Chowdhury N, Figueroa-Magalhaes MC, Pesce C, Jeter SC, Mylander C, Rosman M, Tafra L, Turner BM, Hicks DG, Jensen TA, Miller DV, Armstrong DK, Connolly RM, Fetting JH, Miller RS, Park BH, Stearns V, Visvanathan K, Wolff AC, Cope L.

J Clin Oncol. 2016 Dec 20;34(36):4390-4397. Epub 2016 Oct 31.

41.

Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study.

Connolly RM, Li H, Jankowitz RC, Zhang Z, Rudek MA, Jeter SC, Slater SA, Powers P, Wolff AC, Fetting JH, Brufsky A, Piekarz R, Ahuja N, Laird PW, Shen H, Weisenberger DJ, Cope L, Herman JG, Somlo G, Garcia AA, Jones PA, Baylin SB, Davidson NE, Zahnow CA, Stearns V.

Clin Cancer Res. 2017 Jun 1;23(11):2691-2701. doi: 10.1158/1078-0432.CCR-16-1729. Epub 2016 Dec 15.

42.

Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.

Robarge JD, Desta Z, Nguyen AT, Li L, Hertz D, Rae JM, Hayes DF, Storniolo AM, Stearns V, Flockhart DA, Skaar TC, Henry NL.

Breast Cancer Res Treat. 2017 Feb;161(3):453-461. doi: 10.1007/s10549-016-4077-4. Epub 2016 Dec 9.

43.

The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer.

Wu X, Zahari MS, Renuse S, Kelkar DS, Barbhuiya MA, Rojas PL, Stearns V, Gabrielson E, Malla P, Sukumar S, Mahajan NP, Pandey A.

Oncotarget. 2017 Jan 10;8(2):2971-2983. doi: 10.18632/oncotarget.13579.

44.

Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy.

Ingle JN, Xie F, Ellis MJ, Goss PE, Shepherd LE, Chapman JW, Chen BE, Kubo M, Furukawa Y, Momozawa Y, Stearns V, Pritchard KI, Barman P, Carlson EE, Goetz MP, Weinshilboum RM, Kalari KR, Wang L.

Cancer Res. 2016 Dec 1;76(23):7012-7023. Epub 2016 Oct 10.

45.

Adjuvant radiation use in older women with early-stage breast cancer at Johns Hopkins.

Pollock YG, Blackford AL, Jeter SC, Wright J, Cimino-Mathews A, Camp M, Harvey S, Asrari F, Schoenborn NL, Stearns V.

Breast Cancer Res Treat. 2016 Nov;160(2):291-296. Epub 2016 Oct 3.

46.

Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer.

Hertz DL, Kidwell KM, Seewald NJ, Gersch CL, Desta Z, Flockhart DA, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM.

Pharmacogenomics J. 2017 Dec;17(6):521-527. doi: 10.1038/tpj.2016.60. Epub 2016 Aug 23.

47.

ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors.

Hertz DL, Henry NL, Kidwell KM, Thomas D, Goddard A, Azzouz F, Speth K, Li L, Banerjee M, Thibert JN, Kleer CG, Stearns V, Hayes DF, Skaar TC, Rae JM.

Physiol Genomics. 2016 Sep 1;48(9):688-98. doi: 10.1152/physiolgenomics.00065.2016. Epub 2016 Aug 19.

48.

Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer.

Parsons HA, Beaver JA, Cimino-Mathews A, Ali SM, Axilbund J, Chu D, Connolly RM, Cochran RL, Croessmann S, Clark TA, Gocke CD, Jeter SC, Kennedy MR, Lauring J, Lee J, Lipson D, Miller VA, Otto GA, Rosner GL, Ross JS, Slater S, Stephens PJ, VanDenBerg DA, Wolff AC, Young LE, Zabransky DJ, Zhang Z, Zorzi J, Stearns V, Park BH.

Clin Cancer Res. 2017 Jan 15;23(2):379-386. doi: 10.1158/1078-0432.CCR-16-1543. Epub 2016 Aug 3.

49.

Gene Methylation and Cytological Atypia in Random Fine-Needle Aspirates for Assessment of Breast Cancer Risk.

Stearns V, Fackler MJ, Hafeez S, Bujanda ZL, Chatterton RT, Jacobs LK, Khouri NF, Ivancic D, Kenney K, Shehata C, Jeter SC, Wolfman JA, Zalles CM, Huang P, Khan SA, Sukumar S.

Cancer Prev Res (Phila). 2016 Aug;9(8):673-682. doi: 10.1158/1940-6207.CAPR-15-0377. Epub 2016 Jun 3.

50.

A Clinicopathologic Analysis of 45 Patients With Metaplastic Breast Carcinoma.

Cimino-Mathews A, Verma S, Figueroa-Magalhaes MC, Jeter SC, Zhang Z, Argani P, Stearns V, Connolly RM.

Am J Clin Pathol. 2016 Mar;145(3):365-72. doi: 10.1093/ajcp/aqv097. Epub 2016 Feb 19.

PMID:
27124919

Supplemental Content

Loading ...
Support Center